



Mechanical circulatory support for cardiogenic shock in takotsubo syndrome

Victoria L. Cammann · Victor Schweiger · Konrad A. Szawan · Davide Di Vece · David Niederseer · Michael Würdinger, et al. [full author details at the end of the article]

Received: 21 June 2025 / Accepted: 1 December 2025
© The Author(s) 2026

Abstract

Background Cardiogenic shock complicates takotsubo syndrome (TTS) in approximately 10% of cases. The effectiveness of mechanical circulatory support (MCS) for managing cardiogenic shock in TTS remains unknown.


Methods We assessed outcomes in TTS patients with cardiogenic shock who received MCS compared to medical therapy only by using data from the International Takotsubo Registry. Two independent propensity scores were computed to investigate outcomes of patients with an intra-aortic balloon pump (IABP) vs. medical therapy only (1:2 propensity score matched cohort) and patients with an Impella vs. medical therapy only (1:1 propensity score matched cohort). The primary endpoint was in-hospital mortality and the secondary outcomes included MCS-related complications.

Graphical Abstract

Mechanical circulatory support for cardiogenic shock in Takotsubo Syndrome


IABP vs. Medical therapy only

1:2 propensity score matching



Impella vs. Medical therapy only

1:1 propensity score matching



Results Among 3740 eligible patients, 309 (8.3%) patients had cardiogenic shock, of whom 112 (36.2%) had MCS and 197 (63.8%) had medical therapy only. After propensity-score matching, the use of an IABP was found to be associated with a lower in-hospital mortality rate than medical therapy only (14.5% vs. 35.5%, $P=0.002$), while mortality rates in the Impella group and medical therapy only group were comparable (25.0% vs. 29.2%, $P=0.75$). MCS-related complications occurred in 6.0% of the IABP cohort and in 31.3% of Impella cohort.

Conclusion Active MCS has been increasingly used for the management of cardiogenic shock in patients with TTS. This observational study could not demonstrate an association with improved mortality with an Impella device, but possibly with an IABP when compared to patients with medical management only. MCS-related complications occurred more frequently in the Impella cohort than in the IABP cohort. Further data are required to confirm results of the present study.

Keywords Takotsubo syndrome · Cardiogenic shock · Mechanical circulatory support · Mortality

Abbreviations

ECMO	Extracorporeal membrane oxygenation
GUSTO	Global Use of Strategies to Open Occluded Coronary Arteries
IABP	Intra-aortic balloon pump
InterTAK Registry	International Takotsubo Registry
IQR	Interquartile range
LVEDP	Left-ventricular end-diastolic pressure
LVOTO	Left-ventricular outflow tract obstruction
MCS	Mechanical circulatory support
OHCA	Out-of-hospital cardiac arrest
RETAKO	Registry on Takotsubo syndrome
SD	Standard deviation
SMD	Standardized mean difference
TTS	Takotsubo syndrome

Introduction

Takotsubo syndrome (TTS) is an increasingly recognized acute heart failure syndrome characterized by myocardial stunning involving the left ventricle [1]. The incidence rates of severe complications in TTS are comparable to rates

observed in acute myocardial infarction [2]. In particular, cardiogenic shock represents a major determinant of acute-phase mortality and occurs in approximately 10% of cases [3]. Poor outcomes in patients with TTS and cardiogenic shock have been reported, with a mortality rate of ranging from 15–30% [3–5]. Mechanical circulatory support (MCS) including intra-aortic balloon pump (IABP), microaxial flow pump (Impella), and extracorporeal membrane oxygenation (ECMO) represents a therapeutic alternative. It may provide greater hemodynamic support than inotropic/vasopressor therapy alone. Current evidence on MCS application in TTS complicated by cardiogenic shock is limited to case reports and small case series without control group suggesting that the use of MCS as a bridge-to-recovery might be associated with improved survival [6–13]. The aim of the present study was to generate first insights into the outcomes and safety of IABP and an Impella device compared to medical therapy alone in TTS patients with cardiogenic shock.

Methods

Study design

The International Takotsubo Registry (InterTAK Registry) is an international retrospective and prospective registry including patients with TTS from 56 participating sites in 16 countries [14]. Patients are eligible for inclusion in the registry if the International Takotsubo Diagnostic Criteria (InterTAK Diagnostic Criteria) are met [15]. In the InterTAK Registry, data on demographics, medical history, ECG findings, laboratory values, acute cardiac care measures, and in-hospital complications are captured by central chart review by core team members. Follow-up data are obtained from standardized telephone interviews, chart reviews, or outpatient visits.

The respective local ethics committees or investigational review boards reviewed the study protocol at each collaboration site. Due to the partly retrospective nature of the study, ethics committees of most study centers waived the need for informed consent. At centers where the ethics committees or investigational review boards required informed consent or where patients were included prospectively, formal written consent was obtained from patients or surrogates.

Study population

For the present study, patients from the InterTAK Registry with TTS complicated by cardiogenic shock were selected. The diagnosis of cardiogenic shock was made by clinical assessment at each collaborating site. Furthermore, shock management strategies were registered. These included medical only, the use of MCS including microaxial left

ventricular assist devices (an Impella), IABP, or ECMO, or the use of multiple MCS devices. The shock management strategy was decided at the discretion of the treating physicians at the participating sites. Patients in whom cardiogenic shock was managed without MCS were classified as having received medical therapy only. Patients who received MCS were classified based on the hemodynamic support in IABP, Impella, or ECMO group. The ECMO group includes patients with ECMO support only or in combination with other MCS devices such as IABP (IABP+ECMO) or Impella (ECMELLA).

Outcomes

The primary outcome was in-hospital mortality. As secondary outcome, device-related complications (limb ischemia, compartment syndrome, retroperitoneal hematoma, arterial thrombosis, aneurysm, minor and major bleeding) were considered as safety endpoints in patients who received MCS. Bleeding events were classified according to Global Use of Strategies To Open Coronary arteries (GUSTO) criteria [16].

Statistical analyses

Continuous variables are expressed as mean $\pm$ standard deviation (SD) or median with interquartile range (IQR) and were tested for differences by using the Student's *t*-test or Mann Whitney *U*-test, respectively. Categorical variables are summarized as frequencies and percentages and were analyzed using Pearson's chi-square test or Fisher's exact test. Multiple group comparisons were conducted with a one-way analysis of variance or the Kruskal–Wallis test.

To assess the association between in-hospital mortality, two independent propensity scores were computed for the use of an IABP or an Impella device. Patients with an IABP were 1:2 matched to patients with medical therapy only and patients with an Impella device were 1:1 matched to patients with medical therapy only. Propensity score matching was performed using a 1:2 ratio for the IABP group and a 1:1 ratio for the Impella group to optimize matching quality and adjust for differences in sample size. The following variables were used for the computation of the propensity scores: age, sex, apical type, InterTAK Classification, [2] physical trigger, left ventricular ejection fraction, and out-of-hospital cardiac arrest (OHCA). These parameters were selected as they may represent potential confounding factors or variables that have been associated with adverse outcomes. OHCA was also included in the propensity score as the most common cause of death after OHCA is irreversible hypoxic brain damage, which is unlikely to be influenced by MCS [17].

Covariate balance before and after propensity score matching was evaluated using standardized mean differences (SMD) and is shown in Love Plots. A sufficient balance after

matching was indicated by an SMD threshold of less than 0.1 for all covariates.

A two-sided *P*-value < 0.05 was considered statistically significant. SPSS version 29.0 (IBM Corp., Armonk, NY, USA) and R Version 4.1 (R Foundation for Statistical Computing, Vienna, Austria) were used for statistical analyses, and Prism 8 (GraphPad, La Jolla, CA, USA) for figure design.

Results

Study cohort

Of a total of 3740 patients enrolled in the InterTAK Registry, 309 (8.3%) patients with cardiogenic shock were included in the study (Fig. 1). The mean age of the unmatched cohort was 64.6 ± 14.3 years and 69.8% were female. The mean left ventricular ejection fraction was $29.4 \pm 11.6\%$, and the mean left ventricular end-diastolic pressure was 25.1 ± 8.9 mmHg. The percentages of patients who required mechanical ventilation and received inotropic/vasopressor support with or without MCS were 71.8% and 75.6%, respectively. The in-hospital mortality rate was 25.6%. Characteristics of the unmatched cohort are detailed in Table 1.

Use of mechanical circulatory support

Of the 309 patients with cardiogenic shock, MCS was used in 112 (36.2%) patients while 197 (63.8%) patients received medical therapy only (Table 1, Fig. 1). Among patients who received MCS, 69 (61.6%) had an IABP, 24 (21.4%) had an Impella device ($N = 3$ with Impella 2.5, $N = 10$ with Impella CP, and in 11 the type of Impella was unknown), and 11 (9.8%) had ECMO. Five patients received ECMO in addition to Impella (ECMELLA) and three patients received IABP + ECMO. Over the study period, the utilization of IABP declined after 2010, while active MCS was more frequently used during the last 6 years of enrollment (Fig. 2). Median MCS times were 1.5 days in the IABP group and 2.0 days in the Impella group (Table 1).

Outcome analysis

After propensity score matching, 69 patients with an IABP were compared to 138 patients with medical therapy only and 24 patients with an Impella device were compared to 24 patients with medical therapy only (Table 2). Median support time was 1.5 (IQR, 1.00–3.25) days in the IABP group and 2.0 (IQR, 1.00–2.00) days in the Impella group. In the matched

cohort, the use of IABP was found to be associated with a lower in-hospital mortality rate than medical therapy only (14.5% vs. 35.5%, $P=0.002$), while in-hospital mortality in the Impella group and medical therapy group were comparable (25.0% vs. 29.2%, $P=0.75$). Covariate balance before and after the propensity score matching is shown in Supplementary Fig. 1.

MCS-related complications

Among the 119 patients who received MCS, data on device-related complications were available for 82 patients. A total of 14 (17.1%) patients had MCS-related complications. MCS-related complications were more frequently observed in patients with the Impella or other MCS devices and were the lowest in patients with IABP (31.3% vs. 37.5% vs. 6.0%, $P=0.003$). Limb ischemia was the most frequent complication and occurred in 6.0% of patients with IABP, 31.3% of patients with an Impella device, and in 37.5% of those who underwent ECMO only or received a combination of such devices. Major bleeding complications were observed in 1 patient who had hemorrhagic shock after ECMO removal (Table 3).

Discussion

In this international registry study, we assessed the outcomes of patients with TTS and cardiogenic shock who were treated with MCS compared to those who received medical therapy

alone. MCS devices were used in one-third of cases, with most cases involving the use of IABP or an Impella device. Compared to with medical therapy only, usage of an Impella device was not significantly associated with improved survival, while an IABP was associated with lower mortality when compared to propensity score-matched controls with medical therapy only. The use of MCS was associated with device-related complications in many patients, with the highest rates associated with large-diameter devices.

In the current study, the incidence of cardiogenic shock was nearly 9%, which is consistent with previous studies indicating an incidence ranging from 4 to 20% [18–21]. Contemporary case reports have suggested favorable outcomes when using MCS to manage cardiogenic shock in TTS. Data from a recent meta-analysis including 93 case reports found a pooled survival of nearly 95% and myocardial recovery in all non-fatal cases [6]. However, these positive findings could be subject to publication bias, as reports may disproportionately represent cases with favorable outcomes over those with negative ones.

The pathophysiology of TTS is likely related to a complex multifactorial pathogenesis involving catecholamines and increased sympathetic overactivity leading to microvascular dysfunction [22, 23]. Therefore, inotropic agents should be carefully administered or even avoided. Since the etiology of hypotension/cardiogenic shock in TTS is multifactorial [24, 25], hemodynamic deterioration can be further aggravated by LVOTO, as determined by hypercontractility of the basal segments, and is often associated with moderate-to-severe




Fig. 1 Study population. *Includes 11 patients with ECMO, 5 patients with ECMO and Impella (ECMELLA), and 3 patients with IABP and ECMO. ECMO, extracorporeal membrane oxygenation;

IABP, intra-aortic balloon pump; InterTAK Registry International Takotsubo Registry; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; OHCA, out-of-hospital cardiac arrest

Table 1 Characteristics of TTS patients with cardiogenic shock stratified by treatment regimen

	Total study cohort <i>N</i> = 309	Medical Therapy only <i>N</i> = 197	IABP only <i>N</i> = 69	Impella only <i>N</i> = 24	Other MCS ^o <i>N</i> = 19	<i>P</i> value
Demographics						
Female sex—no./total no. (%)	243/309 (69.8)	161/197 (81.7)	52/69 (75.4)	21/24 (87.5)	9/19 (47.4)	0.004
Age—yr—mean ± SD	64.6 ± 14.3 (<i>N</i> = 309)	64.6 ± 15.1 (<i>N</i> = 197)	64.8 ± 13.7 (<i>N</i> = 69)	68.8 ± 9.9 (<i>N</i> = 24)	58.5 ± 12.1 (<i>N</i> = 19)	0.14
Height—m—mean ± SD	1.63 ± 0.09 (<i>N</i> = 216)	1.62 ± 0.09 (<i>N</i> = 131)	1.61 ± 0.10 (<i>N</i> = 52)	1.66 ± 0.07 (<i>N</i> = 21)	1.71 ± 0.13 (<i>N</i> = 12)	0.005
BMI—kg/m ² —mean ± SD	24.6 ± 5.8 (<i>N</i> = 12)	24.2 ± 5.7 (<i>N</i> = 139)	23.9 ± 4.6 (<i>N</i> = 57)	26.6 ± 5.0 (<i>N</i> = 21)	28.7 ± 9.6 (<i>N</i> = 12)	0.018
Takotsubo Type—no./total no. (%)						
Apical	242/309 (69.5)	146/197 (74.1)	60/69 (87.0)	23/24 (95.8)	13/19 (68.4)	0.015
InterTAK Classification—no./total no. (%)						
Class I: TTS related to emotional stress	29/309 (9.4)	14/197 (7.1)	9/69 (13.0)	4/24 (16.7)	2/19 (10.5)	0.28
Class II: TTS related to physical stress						
Class IIa: TTS secondary to physical activities, medical conditions, or procedures	172/309 (55.7)	113/197 (57.4)	35/69 (50.7)	8/24 (33.3)	16/19 (84.2)	0.007
Class IIb: TTS secondary to acute neurological disorders	39/309 (12.6)	31/197 (15.7)	6/69 (8.7)	2/24 (8.3)	0/19 (0)	0.12
Class III: TTS without an identifiable triggering factor	62/309 (20.1)	35/197 (17.8)	18/69 (26.1)	8/24 (33.3)	1/19 (5.3)	0.06
TTS related to both physical and emotional stress	7/309 (2.3)	4/197 (2.0)	1/69 (1.4)	2/24 (8.3)	0/19 (0)	0.2
Cardiac biomarkers on admission—median (IQR)						
Troponin—factor increase in ULN "	13.86 (2.91–43.83) <i>N</i> = 245	10.89 (2.18–37.07) <i>N</i> = 159	30.14 (8.40–62.86) <i>N</i> = 55	10.74 (1.93–50.07) <i>N</i> = 19	7.94 (3.00–17.00) <i>N</i> = 12	0.014
Creatine kinase—factor increase in ULN	1.02 (0.60–2.09) <i>N</i> = 217	0.96 (0.49–2.06) <i>N</i> = 138	1.06 (0.70–1.833) <i>N</i> = 48	1.51 (0.67–2.87) <i>N</i> = 20	0.98 (0.63–6.53) <i>N</i> = 11	0.74
BNP- factor increase in ULN \$	8.66 (2.29–38.12) <i>N</i> = 146	8.43 (2.13–36.5) <i>N</i> = 90	10.05 (2.45–40.41) <i>N</i> = 37	8.33 (2.20–53.89) <i>N</i> = 18	26.82 (4.04–85.56) <i>N</i> = 8	0.69
Inflammatory markers on admission—median (IQR)						
CRP—mg/l	7.00 (1.40–29.80) <i>N</i> = 203	7.08 (1.60–35.00) <i>N</i> = 127	4.80 (0.48–18.90) <i>N</i> = 47	7.04 (2.48–45.08) <i>N</i> = 21	9.40 (2.00–70.90) <i>N</i> = 11	0.21
WBC—10 ³ /μl	12.50 (9.80–17.98) <i>N</i> = 271	12.05 (9.78–17.22) <i>N</i> = 170	13.35 (9.88–20.08) <i>N</i> = 66	13.90 (10.50–15.73) <i>N</i> = 21	15.22 (9.19–22.50) <i>N</i> = 14	0.63
ECG on admission—no./total no. (%)						
Sinus rhythm	234/272 (67.2)	153–175 (87.4)	51/60 (85.0)	19/22 (86.4)	11/15 (73.3)	0.50
ST-segment elevation	136/274 (78.7)	92–177 (52.0)	33/61 (54.1)	4/22 (18.2)	7/14 (50.0)	0.22
ST-segment depression	33/254 (9.5)	23–167 (13.8)	7/52 (13.5)	3/22 (13.6)	0/13 (0)	0.56
T-wave inversion	93/253 (72.7)	61–166 (36.7)	20/52 (38.5)	12/22 (54.5)	0/13 (0)	0.014

Table 1 (continued)

	Total study cohort <i>N</i> = 309	Medical Therapy only <i>N</i> = 197	IABP only <i>N</i> = 69	Impella only <i>N</i> = 24	Other MCS ^o <i>N</i> = 19	<i>P</i> value
QTc—ms	465.7 ± 56.6 (<i>N</i> = 217)	466.1 ± 54.7 (<i>N</i> = 143)	464.4 ± 63.9 (<i>N</i> = 42)	472.6 ± 62.0 (<i>N</i> = 22)	450.4 ± 41.6 (<i>N</i> = 10)	0.78
Hemodynamics—mean ± SD						
Heart rate—beats/ min #	102.0 ± 26.8 (<i>N</i> = 239)	98.8 ± 27.2 (<i>N</i> = 147)	106.6 ± 21.9 (<i>N</i> = 56)	109.9 ± 22.6 (<i>N</i> = 23)	104.1 ± 41.6 (<i>N</i> = 13)	0.12
Systolic blood pressure—mm Hg #	113.1 ± 32.8 (<i>N</i> = 257)	113.3 ± 30.6 (<i>N</i> = 156)	113.8 ± 40.0 (<i>N</i> = 62)	111.3 ± 25.5 (<i>N</i> = 24)	110.2 ± 34.8 (<i>N</i> = 15)	0.97
Diastolic blood pressure—mm Hg #	68.3 ± 19.9 (<i>N</i> = 246)	69.5 ± 19.5 (<i>N</i> = 148)	66.0 ± 23.4 (<i>N</i> = 60)	70.9 ± 15.5 (<i>N</i> = 23)	62.7 ± 12.6 (<i>N</i> = 15)	0.41
Left ventricular ejection frac- tion—%—‡	29.4 ± 11.6 (<i>N</i> = 293)	31.0 ± 10.7 (<i>N</i> = 186)	30.2 ± 13.6 (<i>N</i> = 65)	18.8 ± 6.6 (<i>N</i> = 24)	23.3 ± 8.7 (<i>N</i> = 18)	< 0.001
Left ventricular end-diastolic pres- sure—mm Hg	25.1 ± 8.9 (<i>N</i> = 163)	23.8 ± 8.1 (<i>N</i> = 108)	25.7 ± 8.6 (<i>N</i> = 35)	34.2 ± 9.1 (<i>N</i> = 10)	27.1 ± 13.3 (<i>N</i> = 10)	0.003
Cardiovascular risk factors/history—no./total no. (%)						
Hypertension	169/306 (48.6)	107/196 (54.6)	36/67 (53.7)	12/24 (50.0)	14/19 (73.7)	0.40
Diabetes mellitus	69/308 (19.8)	43/196 (21.9)	16/69 (23.2)	6/24 (25.0)	4/19 (21.1)	0.98
Current smoking	66/290 (19.0)	43/183 (23.5)	10/65 (15.4)	7/23 (30.4)	6/19 (31.6)	0.61
Hypercholester- olemia	68/301 (19.5)	41/192 (21.4)	15/66 (22.7)	7/24 (29.2)	5/19 (26.3)	0.82
Family history of CAD	31/252 (8.9)	18/156 (11.5)	6/56 (10.7)	6/22 (27.3)	1/18 (5.6)	0.14
Acute cardiac care treatment—no./total no. (%)						
Inotropic agents/ vasopressors	263/309 (75.6)	169/197 (85.8)	54/69 (78.3)	21/24 (87.5)	19/19 (100)	0.11
Respiratory therapy	250/309 (71.8)	161/197 (81.7)	25/69 (75.4)	21/24 (87.5)	16/19 (84.2)	0.52
Out-of-hospital car- diac arrest—no./ total no. (%)	43/239 (12.4)	31/147 (21.1)	8/50 (16.0)	2/23 (8.7)	2/19 (10.5)	0.37
Support time (days)—median (IQR)	2.00 (1.00–3.00) <i>N</i> = 57	-	1.50 (1.00–3.25) <i>N</i> = 26	2.00 (1.00–2.00) <i>N</i> = 17	3.00 (2.00–7.00) <i>N</i> = 14	0.06
In-hospital death— no./total no. (%)	89/309 (25.6)	62/197 (31.5)	10/69 (14.5)	6/24 (25.0)	11/19 (57.9)	0.001

[§]Including upper limits of the normal range for troponin T, high-sensitivity troponin T, and troponin I

[†]Including upper limits of the normal range for brain natriuretic peptide and the N-terminal of prohormone brain natriuretic peptide

[‡]Data obtained during catheterization or echocardiography; if both results were available data from catheterization were used

[#]Data on admission, heart rate and blood pressure may have been influenced by inotropic agents/vasopressors

BMI body mass index, *BNP* brain natriuretic peptide, *CRP* c-reactive protein, *CAD* coronary artery disease, *ECG* electrocardiogram, *IQR* inter-quartile range, *IABP* intra-aortic balloon pump, *MCS* mechanical circulatory support, *QTc* QT interval corrected for heart rate, *TTS* Takotsubo syndrome, *SD* standard deviation, *ULN* upper limit of the normal, *WBC* white blood cell count

^oOther MCS includes 11 patients with ECMO, 5 patients with ECMELLA (ECMO + Impella) and 3 patients with IABP + ECMO

mitral regurgitation [26–29]. In the acute phase, TTS can be difficult to distinguish from ACS, particularly in the presence of CAD [30, 31]. Transient thrombotic occlusion with spontaneous thrombolysis may result in angiographically

normal or near-normal coronary arteries, thereby mimicking TTS. Cardiac MRI has been proposed as a helpful diagnostic tool in this context. The colocalization of myocardial edema and typical wall motion abnormalities in the absence of late




Fig. 2 Mechanical circulatory support over time. Usage of mechanical circulatory support (MCS) over time. The use of the IABP has declined, while the Impella and other MCS devices such as the ECMO, ECMELLA or a combination of the IABP and ECMO was more frequently used during the later years of the study. Data

for the period from 1999 to 2001 are not presented in the figure as only 1 patient with IABP was included during this period. *Other includes ECMELLA, ECMO, and IABP+ECMO. ECMELLA, Impella+extracorporeal membrane oxygenation; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump

gadolinium enhancement has been suggested to provide incremental diagnostic value [32].

Management of cardiogenic shock in TTS patients represents a clinical challenge, especially in the presence of LVOTO, which is estimated to be present in 7–25% of cases and can be further aggravated by inotropes or IABP [33–35]. Therefore, an Impella seems a promising therapeutic concept since left ventricular unloading can reduce filling pressures, LVOTO can be bridged, and coronary microcirculation may be improved [8, 36].

In 2018, investigators from RETAKO Registry demonstrated that LVOTO was the main predictor for hemodynamic deterioration in patients with TTS and cardiogenic shock [37]. In our study, which includes data dating back to 1999, LVOTO was not routinely measured, suggesting that the overall clinical significance of LVOTO was considerably lower at that time. However, the presence or absence of LVOTO may be crucial for device selection in patients with TTS and cardiogenic shock and should be routinely measured.

In the present study, the use of an IABP was associated with improved survival compared to medical therapy alone. IABP augments coronary perfusion during diastole and may also improve microvascular perfusion offering a treatment option for TTS patients with shock and coronary slow flow.

Furthermore, one case series suggested that IABP as an adjunctive therapy in patients with TTS and subarachnoid hemorrhage ameliorated cardiogenic shock and cerebral vasospasms [38]. However, IABP may not be a therapeutic option for shock management in the presence of LVOTO, which has been reported in a non-negligible proportion of patients with TTS in association with hemodynamic deterioration. While in our study we did not find a mortality reduction in the Impella group in comparison to matched controls, the presence of physical triggers may have mitigated a potential treatment effect. Patients treated with an Impella presented with more severe hemodynamic compromise and the use of the Impella 2.5 model in some cases may also have influenced outcomes. TTS is an underrated condition and encompasses a heterogeneous population with a wide range of triggering events (e.g., acute neurologic disorders) and especially those with cardiogenic shock had a high acute comorbidity burden. These factors can significantly influence prognosis, thus making it challenging to evaluate the true effectiveness of MCS devices in TTS.

Over the entire study period, the use of IABP declined after 2010, while active MCS devices have increasingly been used. One possible explanation for this trend may be the neutral effect of IABP in AMI-related cardiogenic shock and the corresponding downgrade from a Class IC recommendation

Table 2 Characteristics of the propensity score matched study cohorts

	1:2 Matched study cohort			1:1 Matched study cohort		
	Medical therapy only	IABP only	<i>P</i> value	Medical therapy only	Impella only	<i>P</i> value
	<i>N</i> = 138	<i>N</i> = 69		<i>N</i> = 24	<i>N</i> = 24	
Demographics						
Female sex—no./total no. (%)	109/138 (79.0)	52/69 (75.4)	0.68	21/24 (87.5)	21/24 (87.5)	1.0
Age—yr—mean ± SD	65.9 ± 14.1 (<i>N</i> = 138)	64.8 ± 13.7 (<i>N</i> = 69)	0.58	68.0 ± 14.6 (<i>N</i> = 24)	68.8 ± 9.9 (<i>N</i> = 24)	0.82
Height—m—mean ± SD	1.63 ± 0.09 (<i>N</i> = 97)	1.61 ± 0.10 (<i>N</i> = 52)	0.30	1.68 ± 0.09 (<i>N</i> = 15)	1.66 ± 0.07 (<i>N</i> = 21)	0.37
BMI- kg/m ² —mean ± SD	25.0 ± 6.7 (<i>N</i> = 99)	23.9 ± 4.6 (<i>N</i> = 57)	0.24	26.2 ± 5.4 (<i>N</i> = 15)	26.6 ± 5.0 (<i>N</i> = 21)	0.81
Takotsubo Type—no./total no. (%)						
Apical	121/138 (87.7)	60/69 (87.0)	0.88	23/24 (95.8)	23/24 (95.8)	1.0
InterTAK Classification—no./total no. (%)						
Class I: TTS related to emotional stress	13/138 (9.4)	9/69 (13.0)	0.43	4/24 (16.7)	4/24 (16.7)	1.0
Class II: TTS related to physical stress						
Class IIa: TTS secondary to physical activities, medical conditions, or procedures	71/138 (51.4)	35/69 (50.7)	0.92	9/24 (37.5)	8/24 (33.3)	0.76
Class IIb: TTS secondary to acute neurological disorders	18/138 (13.0)	6/69 (8.7)	0.36	2/24 (8.3)	2/24 (8.3)	1.0
Class III: TTS without an identifiable triggering factor	32/138 (23.2)	18/69 (26.1)	0.65	7/24 (29.2)	8/24 (33.3)	1.0
TTS related to both physical and emotional stress	4/138 (2.9)	1/69 (1.4)	0.52	2/24 (8.3)	2/24 (8.3)	0.75
Cardiac biomarkers on admission—median (IQR)						
Troponin—factor increase in ULN "	9.67 (2.00–31.29) <i>N</i> = 102	30.14 (8.40–62.86) <i>N</i> = 55	0.001	15.15 (3.73–59.34) <i>N</i> = 21	10.74 (1.93–50.07) <i>N</i> = 19	0.64
Creatine kinase—factor increase in ULN	0.84 (0.49–2.04) <i>N</i> = 84	1.06 (0.70–1.83) <i>N</i> = 48	0.41	0.92 (0.59–1.68) <i>N</i> = 16	1.51 (0.67–2.87) <i>N</i> = 20	0.59
BNP—factor increase in ULN \$	12.01 (2.68–54.82) <i>N</i> = 58	10.05 (2.45–40.41) <i>N</i> = 37	0.55	35.73 (2.77–101.2) <i>N</i> = 14	8.33 (2.20–53.89) <i>N</i> = 18	0.19
Inflammatory markers on admission—median (IQR)						
CRP—mg/l	9.60 (1.65–42.40) <i>N</i> = 81	4.80 (0.48–18.90) <i>N</i> = 47	0.07	8.90 (1.70–70.90) <i>N</i> = 15	7.04 (2.48–45.08) <i>N</i> = 21	0.96
WBC—10 ³ /μl	12.20 (9.49–17.75) <i>N</i> = 113	13.35 (9.88–20.08) <i>N</i> = 66	0.31	13.72 (10.59–21.36) <i>N</i> = 22	13.90 (10.50–15.73) <i>N</i> = 21	0.28
ECG on admission—no./total no. (%)						
Sinus rhythm	102/122 (83.6)	51/60 (85.0)	0.81	20/23 (87.0)	19/22 (86.4)	0.95
ST-segment elevation	56/122 (45.9)	33/61 (54.1)	0.30	11/23 (47.8)	4/22 (18.2)	0.035
ST-segment depression	17/119 (14.3)	7/52 (13.5)	0.89	2/23 (8.7)	3/22 (13.6)	0.6
T-wave inversion	40/118 (33.9)	20/52 (38.5)	0.57	8/23 (34.8)	12/22 (54.5)	0.18
QTc—ms	467.9 ± 52.6 (<i>N</i> = 95)	464.4 ± 63.9 (<i>N</i> = 42)	0.74	472.0 ± 66.3 (<i>N</i> = 21)	472.6 ± 62.0 (<i>N</i> = 22)	0.98

Table 2 (continued)

	1:2 Matched study cohort			1:1 Matched study cohort		
	Medical therapy only <i>N</i> = 138	IABP only <i>N</i> = 69	<i>P</i> value	Medical therapy only <i>N</i> = 24	Impella only <i>N</i> = 24	<i>P</i> value
Hemodynamics—mean ± SD						
Heart rate—beats/min #	98.0 ± 27.8 (<i>N</i> = 104)	106.6 ± 21.9 (<i>N</i> = 56)	0.048	93.6 ± 16.1 (<i>N</i> = 19)	109.9 ± 22.6 (<i>N</i> = 23)	0.012
Systolic blood pressure—mm Hg #	113.7 ± 29.5 (<i>N</i> = 107)	113.8 ± 40.0 (<i>N</i> = 62)	0.98	113.4 ± 29.4 (<i>N</i> = 22)	111.3 ± 25.5 (<i>N</i> = 24)	0.8
Diastolic blood pressure—mm Hg #	67.6 ± 18.0 (<i>N</i> = 104)	66.0 ± 23.4 (<i>N</i> = 60)	0.62	65.6 ± 14.4 (<i>N</i> = 22)	70.9 ± 15.5 (<i>N</i> = 23)	0.24
Left ventricular ejection fraction—%—‡	29.0 ± 9.6 (<i>N</i> = 137)	30.2 ± 13.6 (<i>N</i> = 65)	0.53	19.4 ± 5.7 (<i>N</i> = 24)	18.8 ± 6.6 (<i>N</i> = 24)	0.017
Left ventricular end-diastolic pressure—mm Hg	25.1 ± 8.0 (<i>N</i> = 78)	25.7 ± 8.6 (<i>N</i> = 35)	0.7	24.8 ± 7.9 (<i>N</i> = 12)	34.2 ± 9.1 (<i>N</i> = 10)	0.74
Cardiovascular risk factors/history—no./total no. (%)						
Hypertension	76/137 (55.5)	36/67 (53.7)	0.81	16/24 (66.7)	12/24 (50.0)	0.24
Diabetes mellitus	34/69 (24.8)	16/69 (23.2)	0.8	8/24 (33.3)	6/24 (25.0)	0.53
Current smoking	34/138 (24.6)	10/65 (15.4)	0.35	4/24 (16.7)	7/23 (30.4)	0.21
Hypercholesterolemia	33/134 (24.6)	15/66 (22.7)	0.78	7/24 (29.2)	7/24 (29.2)	1.0
Family history of CAD	11/109 (10.1)	6/56 (10.7)	0.90	6/22 (27.3)	6/22 (27.3)	1.0
Acute cardiac care treatment—no./total no. (%)						
Inotropic agents/vasopressors	115/138 (83.3)	54/69 (78.3)	0.37	21/24 (87.5)	21/24 (87.5)	1.0
Respiratory therapy	105/138 (76.1)	25/69 (75.4)	0.91	16/24 (66.7)	21/24 (87.5)	0.086
Out-of-hospital cardiac arrest—no./total no. (%)	16/138 (11.6)	8/50 (16.0)	1.0	2/24 (8.3)	2/23 (8.7)	1.0
Support time (days)—median (IQR)	-	1.50 (1.00–3.25) <i>N</i> = 26	-	-	2.00 (1.00–2.00) <i>N</i> = 17	-
In-hospital death—no./total no. (%)	49/138 (35.5)	10/69 (14.5)	0.002	7/24 (29.2)	6/24 (25.0)	0.75

§Including upper limits of the normal range for troponin T, high-sensitivity troponin T, and troponin I

†Including upper limits of the normal range for brain natriuretic peptide and the N-terminal of prohormone brain natriuretic peptide

‡Data obtained during catheterization or echocardiography; if both results were available data from catheterization were used

#Data on admission, heart rate and blood pressure may have been influenced by inotropic agents/vasopressors

BMI body mass index, *BNP* brain natriuretic peptide, *CRP* c-reactive protein, *CAD* coronary artery disease, *ECG* electrocardiogram, *IQR* interquartile range, *IABP* intra-aortic balloon pump, *QTc* QT interval corrected for heart rate, *SD* standard deviation, *TTS* Takotsubo syndrome, *ULN* upper limit of the normal, *WBC* white blood cell count

to a Class III recommendation in current guidelines for myocardial revascularization [39]. This transition also seems relevant for managing cardiogenic shock in patients with TTS, despite the absence of specific data for TTS and often reliance on acute coronary syndrome protocols. Our study noted a shift from frequent IABP use in early-enrolled TTS patients to an increasing use of an Impella over the years. This period also saw an increase in patients with physical triggers and acute comorbidities, potentially linked to poorer outcomes. The better outcomes with an IABP compared to

medical therapy in TTS patients could not be observed with an Impella device, which showed mortality rates similar to medical therapy alone. This change might be in part also attributed to different clinical profiles, with a higher burden of acute comorbidities for TTS cases in recent years, despite adjustments for confounders in our analysis.

TTS patients may rapidly recover and stabilize over the clinical course, which is also reflected by the overall short support time (median, 2 days). Therefore, TTS seems to be a bridgeable disease, and early initiation of short-term MCS

Table 3 Device-related complications

	IABP only <i>N</i> = 69	Impella only <i>N</i> = 24	Other MCS ^o <i>N</i> = 19	<i>P</i> value
Complications (total)—no./total no. (%)	3/50 (6.0)	5/16 (31.3)	6/16 (37.5)	0.003
Limb ischemia	1/50 (2.0)	2/16 (12.5)	2/16 (12.5)	-
Compartment syndrome	1/50 (2.0)	-	-	-
Retroperitoneal hematoma	1/50 (2.0)	1/16 (6.3)	-	-
Arterial thrombosis	-	1/16 (6.3)	1/16 (6.3)	-
Aneurysm	-	-	1/16 (6.3)	-
Major bleeding*	-	-	1/16 (6.3)	-
Minor bleeding*	-	1/16 (6.3)	1/16 (6.3)	-

*Classified according to GUSTO criteria

^oOther MCS includes 11 patients with ECMO, 5 patients with ECMELLA (ECMO+Impella) and 3 patients with IABP+ECMO

as a bridge-to-recovery may be considered. In our study, one-third of patients with MCS had device-related complications, with most complications occurring in the Impella or other MCS groups and the fewest occurring in patients with an IABP. IABP has a smaller catheter size, which might result in fewer complications than large-diameter devices such as the Impella device or ECMO. The incidence of device-related complications in the Impella cohort were similar to those, which have been observed in the DANGER Trial [40]. Early initiation of MCS and early discontinuation of inotropes could potentially lead to improved survival in TTS complicated by cardiogenic shock. Assessment of LVOTO and measurement of LVEDP is crucial before MCS implantation, and device selection may depend on the presence or absence of LVOTO.

Limitations

The strengths of the study include the use of the largest, international, multicenter cohort of TTS patients with cardiogenic shock, which provided extensive data on patients' characteristics and prognostic factors. This enabled us to generate propensity score matched analyses based on relevant confounders, comparing TTS controls with medical shock management only to TTS patients managed with either an IABP or an Impella. However, some limitations of our study should be considered. This was a registry-based analysis, and the findings should be interpreted cautiously and regarded as hypothesis-generating. Due to the study's observational nature, causality cannot be established. The definition of shock was not standardized and based on documentation as defined by the investigators at each study site. Therefore, patients with different shock stages (SCAI stage A-E) might have been included [41]. The number of patients in the Impella and other MCS groups was small, and we

could not assess the effectiveness of ECMO, ECMELLA, or ECMO combined with IABP. Due to study's real-world and partially retrospective nature, information on LVOTO, dosing and different types of inotropic agents/vasopressors, and no/low-flow time after cardiopulmonary resuscitation was not systematically collected and was not available for this analysis [42]. Furthermore, additional laboratory or hemodynamic parameters beyond those reported were not recorded. Although propensity score matching included relevant confounding factors, residual bias due to unmeasured factors that may influence the outcome cannot be excluded [43]. However, as of today, this study includes the largest available cohort of TTS patients investigating the effectiveness of MCS for managing cardiogenic shock from highly experienced sites.

Conclusion

In this large, multicenter, observational study, MCS devices were increasingly used to manage cardiogenic shock in TTS. The present study with its limitations could not demonstrate an association with improved mortality with an Impella, but possibly with an IABP when compared matched controls with only medical therapy. The use of MCS was associated with device-related complications in a substantial number of patients. TTS patients are a heterogeneous population, and those with cardiogenic shock have a high acute comorbidity burden. Therefore, management of cardiogenic shock in TTS needs to be individually tailored with the selection of MCS based on local expertise to maximize the benefit/risk ratio. Further studies are necessary to verify the present results and to establish a causal relationship.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1007/s00392-025-02832-z>.

Funding Open Access funding enabled and organized by Projekt DEAL. The InterTAK Registry is supported by the Biss Davies Charitable Trust.

Declarations

Dr. Templin has been supported by a donation from H.H. Sheikh Khalifa bin Hamad Al-Thani to the University of Zurich, Switzerland. Dr. Templin has received institutional grants from Abbott Vascular, Medtronic and SMT as well as consulting grants from Biotronik, Microport and Schnell Medical. Dr. Roffi has received institutional research grants from Boston Scientific, Terumo, Medtronic, Biotronic and Cordis. Dr. Böhm is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TTR 219, project number 322900939) and reports personal fees from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, Servier and Vifor during the conduct of the study. Dr. Lüscher reports outside this work research and educational grants to the institution Abbott, Amgen, AstraZeneca, Boehringer-Ingelheim, Daiichi-Sankyo, Menarini Foundation, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi and Vifor and honoraria from Daiichi-Sankyo, Menarini, WorkSuite Inc., USA. Dr. Niederseer discloses honoraria, consultant fees and/or travel expenses outside this work from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Dr. Willmar Schwabe GmbH & Co. KG, Emilwood Service Limited, Gerson Lehman Group (GLG) Consulting, Novartis, Novo Nordisk, Pfizer, walk and feel, and Zoll.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Templin C, Ghadri JR, Diekmann J et al (2015) Clinical features and outcomes of takotsubo (stress) cardiomyopathy. *N Engl J Med* 373(10):929–938
- Ghadri JR, Kato K, Cammann VL et al (2018) Long-term prognosis of patients with takotsubo syndrome. *J Am Coll Cardiol* 72(8):874–882
- Di Vece D, Citro R, Cammann VL et al (2019) Outcomes associated with cardiogenic shock in takotsubo syndrome. *Circulation* 139(3):413–415
- Bengtson JR, Kaplan AJ, Pieper KS et al (1992) Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. *J Am Coll Cardiol* 20(7):1482–1489
- Vallabhajosyula S, Dunlay SM, Murphree DH Jr et al (2019) Cardiogenic shock in takotsubo cardiomyopathy versus acute myocardial infarction: an 8-year national perspective on clinical characteristics, management, and outcomes. *JACC Heart Fail* 7(6):469–476
- Mariani S, Richter J, Pappalardo F et al (2020) Mechanical circulatory support for takotsubo syndrome: a systematic review and meta-analysis. *Int J Cardiol* 316:31–39
- Hanif M, Haider MA, Xi Q, Ali MJ, Khan MA (2020) Takotsubo cardiomyopathy triggered by the death of pets (cats): two case reports. *Cureus* 12(9):e10690
- Rashed A, Won S, Saad M, Schreiber T (2015) Use of the Impella 2.5 left ventricular assist device in a patient with cardiogenic shock secondary to takotsubo cardiomyopathy. *BMJ Case Rep* 2015:bcr2014208354
- Attisano T, Silverio A, Prota C, Briguori C, Galasso G, Citro R (2020) Impella in takotsubo syndrome complicated by left ventricular outflow tract obstruction and severe mitral regurgitation. *ESC Heart Fail* 7(1):306–310
- Nakamura M, Nakagaito M, Hori M, Ueno H, Kinugawa K (2019) A case of takotsubo cardiomyopathy with cardiogenic shock after influenza infection successfully recovered by IMPELLA support. *J Artif Organs* 22(4):330–333
- Foley ED, Diaz R, Castresana MR (2017) Prolonged circulatory support with an Impella assist device in the management of cardiogenic shock associated with takotsubo syndrome, severe sepsis and acute respiratory distress syndrome. *SAGE Open Med Case Rep* 5:2050313X17741013
- Sundaravel S, Alrifai A, Kabach M, Ghumman W (2017) FOLFOLX induced takotsubo cardiomyopathy treated with impella assist device. *Case Rep Cardiol* 2017:8507096
- Napp LC, Westenfeld R, Moller JE et al (2022) Impella mechanical circulatory support for takotsubo syndrome with shock: a retrospective multicenter analysis. *Cardiovasc Revasc Med* 40:113–119
- Ghadri JR, Cammann VL, Templin C (2016) The international Takotsubo registry: rationale, design, objectives, and first results. *Heart Fail Clin* 12(4):597–603
- Ghadri JR, Wittstein IS, Prasad A et al (2018) International expert consensus document on takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. *Eur Heart J* 39(22):2032–2046
- Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 123(23):2736–2747
- Udesen NJ, Moller JE, Lindholm MG et al (2019) Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. *Am Heart J* 214:60–68
- Lyon AR, Bossone E, Schneider B et al (2016) Current state of knowledge on takotsubo syndrome: a position statement from the taskforce on takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 18(1):8–27
- Citro R, Rigo F, D'Andrea A et al (2014) Echocardiographic correlates of acute heart failure, cardiogenic shock, and in-hospital mortality in tako-tsubo cardiomyopathy. *JACC Cardiovasc Imaging* 7(2):119–129
- Schneider B, Athanasiadis A, Schwab J et al (2014) Complications in the clinical course of tako-tsubo cardiomyopathy. *Int J Cardiol* 176(1):199–205
- Stiermaier T, Eitel C, Desch S et al (2016) Incidence, determinants and prognostic relevance of cardiogenic shock in patients with takotsubo cardiomyopathy. *Eur Heart J Acute Cardiovasc Care* 5(6):489–496
- Wittstein IS, Thiemann DR, Lima JA et al (2005) Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med* 352(6):539–548
- Lüscher TF, Templin C (2016) Is takotsubo syndrome a microvascular acute coronary syndrome? Towards of a new definition. *Eur Heart J*. <https://doi.org/10.1093/eurheartj/ehw057>
- Chong CR, Neil CJ, Nguyen TH et al (2013) Dissociation between severity of takotsubo cardiomyopathy and presentation with shock or hypotension. *Clin Cardiol* 36(7):401–406

25. Nguyen TH, Liu S, Ong GJ, Stafford I, Frenneaux MP, Horowitz JD (2017) Glycocalyx shedding is markedly increased during the acute phase of takotsubo cardiomyopathy. *Int J Cardiol* 243:296–299
26. Sharkey SW, Windenburg DC, Lesser JR et al (2010) Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. *J Am Coll Cardiol* 55(4):333–341
27. Citro R, Lyon AR, Meimoun P et al (2015) Standard and advanced echocardiography in takotsubo (stress) cardiomyopathy: clinical and prognostic implications. *J Am Soc Echocardiogr* 28(1):57–74
28. El Mahmoud R, Mansencal N, Pilliere R et al (2008) Prevalence and characteristics of left ventricular outflow tract obstruction in Tako-tsubo syndrome. *Am Heart J* 156(3):543–548
29. Merli E, Sutcliffe S, Gori M, Sutherland GG (2006) Tako-tsubo cardiomyopathy: new insights into the possible underlying pathophysiology. *Eur J Echocardiogr* 7(1):53–61
30. Napp LC, Cammann VL, Jaguszewski M et al (2020) Coexistence and outcome of coronary artery disease in takotsubo syndrome. *Eur Heart J* 41(34):3255–3268
31. Topf A, Mirna M, Paar V et al (2022) Differential diagnosis between takotsubo syndrome and acute coronary syndrome—a prospective analysis of novel cardiovascular biomarkers for a more selective triage. *J Clin Med*. <https://doi.org/10.3390/jcm11112974>
32. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P et al (2011) Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. *JAMA* 306(3):277–286
33. De Backer O, Debonnaire P, Gevaert S, Missault L, Gheeraert P, Muyldermans L (2014) Prevalence, associated factors and management implications of left ventricular outflow tract obstruction in takotsubo cardiomyopathy: a two-year, two-center experience. *BMC Cardiovasc Disord* 14:147
34. Takamura T, Dohi K, Satomi A et al (2012) Intra-aortic balloon pump induced dynamic left ventricular outflow tract obstruction and cardiogenic shock after very late stent thrombosis in the left anterior descending coronary artery. *J Cardiol Cases* 6(5):e137–e140
35. Di Vece D, Silverio A, Bellino M et al (2021) Dynamic left intra-ventricular obstruction phenotype in takotsubo syndrome. *J Clin Med*. <https://doi.org/10.3390/jcm10153235>
36. Hamanaka Y, Sotomi Y, Kobayashi T et al (2020) Dynamic change of coronary microcirculation during cardiocirculatory support by the Impella. *JACC Cardiovasc Interv* 13(1):135–137
37. Almendro-Delia M, Nunez-Gil JJ, Lobo M et al (2018) Short- and long-term prognostic relevance of cardiogenic shock in takotsubo syndrome: results from the RETAKO registry. *JACC Heart Fail* 6(11):928–936
38. Ducruet AF, Albuquerque FC, Crowley RW, Williamson R, Forseth J, McDougall CG (2013) Balloon-pump counterpulsation for management of severe cardiac dysfunction after aneurysmal subarachnoid hemorrhage. *World Neurosurg* 80(6):e347–352
39. Authors/Task Force m, Windecker S, Kolh P et al (2014) 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35(37):2541–2619
40. Moller JE, Engstrom T, Jensen LO et al (2024) Microaxial flow pump or standard care in infarct-related cardiogenic shock. *N Engl J Med* 390(15):1382–1393
41. Baran DA, Grines CL, Bailey S et al (2019) SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. *Catheter Cardiovasc Interv* 94(1):29–37
42. Templin C, Ghadri JR, Napp LC (2015) Takotsubo (stress) cardiomyopathy. *N Engl J Med* 373(27):2689–2691
43. Aguirre Davila L, Weber K, Bavendiek U et al (2019) Digoxin-mortality: randomized vs. observational comparison in the DIG trial. *Eur Heart J* 40(40):3336–3341

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Victoria L. Cammann¹ · Victor Schweiger¹ · Konrad A. Szawan¹ · Davide Di Vece^{2,3} · David Niederseer^{4,5,6} · Michael Würdinger¹ · Alexander Schönberger¹ · Maximilian Schönberger¹ · Iva Koleva¹ · Julien C. Mercier¹ · Rodolfo Citro^{7,8} · Carmine Vecchione^{8,9} · Eduardo Bossone¹⁰ · Sebastiano Gili¹¹ · Michael Neuhaus¹² · Jennifer Franke¹³ · Benjamin Meder¹³ · Miłosz Jaguszewski¹⁴ · Michel Noutsias¹⁵ · Maike Knorr¹⁶ · Thomas Jansen¹⁶ · Fabrizio D'Ascenzo¹⁷ · Wolfgang Dichtl¹⁸ · Dirk von Lewinski¹⁹ · Christof Burgdorf²⁰ · Behrouz Kherad²¹ · Ahmed Elsanhoury²¹ · Carsten Tschöpe²¹ · Vivian Alice Nelki²¹ · Annahita Sarcon²² · Jerold Shinbane²³ · Lawrence Rajan²⁴ · Guido Michels²⁵ · Roman Pfister²⁶ · Alessandro Cuneo²⁷ · Claudius Jacobshagen^{28,29} · Mahir Karakas^{30,31} · Wolfgang Koenig^{32,33} · Alexander Pott³⁴ · Philippe Meyer³⁵ · Marco Roffi³⁵ · Adrian Banning³⁶ · Mathias Wolfrum³⁷ · Florim Cuculi³⁷ · Richard Kobza³⁷ · Thomas A. Fischer³⁸ · Tuija Vasankari³⁹ · K. E. Juhani Airaksinen³⁹ · L. Christian Napp⁴⁰ · Rafal Dworakowski⁴¹ · Philip MacCarthy⁴¹ · Christoph Kaiser⁴² · Stefan Osswald⁴² · Leonarda Galiuto⁴³ · Christina Chan⁴⁴ · Paul Bridgman⁴⁴ · Daniel Beug² · Stephan B. Felix² · Clément Delmas⁴⁵ · Olivier Lairez⁴⁵ · Ekaterina Gilyarova⁴⁶ · Alexandra Shilova⁴⁶ · Mikhail Gilyarov⁴⁶ · Ibrahim El-Battrawy^{47,48} · Ibrahim Akin^{47,48} · Karolina Poledniková⁴⁹ · Petr Toušek⁴⁹ · David E. Winchester⁵⁰ · Michael Massoomi⁵⁰ · Jan Galuszka⁵¹ · Christian Ukena^{52,53} · Gregor Poglajen⁵⁴ · Pedro Carrilho-Ferreira⁵⁵ · Christian Hauck⁵⁶ · Carla Paolini⁵⁷ · Claudio Bilato⁵⁷ · Yoshio Kobayashi⁵⁸ · Ken Kato⁵⁸ · Iwao Ishibashi⁵⁹ · Toshiharu Himi⁶⁰ · Jehangir Din⁶¹ · Ali Al-Shammari⁶¹ · Abhiram Prasad⁶² · Charanjit S. Rihal⁶² · Kan Liu⁶³ · P. Christian Schulze⁶⁴ · Matteo Bianco⁶⁵ · Lucas Jörg⁶⁶ · Hans Rickli⁶⁶ · Gonçalo Pestana⁶⁷ · Thanh H. Nguyen⁶⁸ · Michael Böhm⁵² · Lars S. Maier⁵⁶ · Fausto J. Pinto⁵⁵ · Petr Widimsky⁴⁹ · Ruediger C. Braun-Dullaes⁶⁹ · Wolfgang Rottbauer³⁴ · Gerd Hasenfuß²⁸ · Burkert M. Pieske^{21,70} · Heribert Schunkert^{32,33} · Monika Budnik⁷¹ · Grzegorz Opolski⁷¹ · Holger Thiele⁷² · Johann Bauersachs⁴⁰ · John D. Horowitz⁶⁸ · Carlo Di Mario⁷³ · William Kong⁷⁴ · Mayank Dalakoti⁷⁴ · Yoichi Imori⁷⁵ · Laura Wehling⁷⁶ · Norman Mangner⁷⁶ · Ulrich Gerk⁷⁷ · Thomas Münzel¹⁶ · Filippo Crea⁴³ · Thomas F. Lüscher^{78,79} · Jeroen J. Bax⁸⁰ · Burkhardt Seifert⁸¹ · Jelena R. Ghadri¹ · Christian Templin^{2,78,82} 

✉ Christian Templin
christian.templin@med.uni-greifswald.de

¹ Department of Cardiology, University Heart Center, University Hospital Zurich, and University of Zurich, Zurich, Switzerland

² Internal Medicine B, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, Greifswald 17475, Germany

³ First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy

⁴ Medicine Campus Davos, Davos, Switzerland

⁵ Christine Kühne Center for Allergy Research and Education (CK-CARE), Medicine Campus Davos, Davos, Switzerland

⁶ Center of Translational and Experimental Cardiology, University Hospital Zurich, Zurich, Switzerland

⁷ Heart Department, University Hospital San Giovanni Di Dio E Ruggi d'Aragona, Salerno, Italy

⁸ Department of Vascular Physiopathology, IRCCS Neuromed, Pozzilli, Italy

⁹ Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Salerno, Italy

¹⁰ Division of Cardiology, "Antonio Cardarelli" Hospital, Naples, Italy

¹¹ Centro Cardiologico Monzino, IRCCS, Milan, Italy

¹² Department of Cardiology, Kantonsspital Frauenfeld, Frauenfeld, Switzerland

¹³ Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany

¹⁴ First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland

¹⁵ Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, German Heart Center, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany

¹⁶ Department of Cardiology, University Medical Center Mainz, Mainz, Germany

¹⁷ Division of Cardiology, Department of Medical Sciences, AOU Città Della Salute E Della Scienza, University of Turin, Turin, Italy

¹⁸ University Hospital for Internal Medicine III (Cardiology and Angiology), Medical University Innsbruck, Innsbruck, Austria

¹⁹ Division of Cardiology, Medical University of Graz, Graz, Austria

²⁰ Heart and Vascular Centre Bad Bevensen, Bad Bevensen, Germany

²¹ Department of Cardiology, Charité, Campus Rudolf Virchow, Berlin, Germany

²² Section of Cardiac Electrophysiology, Department of Medicine, University of California-San Francisco, San Francisco, CA, USA

²³ Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

- 24 TJ Health Partners Heart and Vascular, Glasgow, KY, USA
- 25 Akademisches Lehrkrankenhaus der, Klinik Für Akut- Und Notfallmedizin, St.-Antonius-Hospital gGmbH, RWTH Aachen, Eschweiler, Germany
- 26 Department of Internal Medicine III, Heart Center University of Cologne, Cologne, Germany
- 27 Krankenhaus "Maria Hilf" Medizinische Klinik, Stadtlohn, Germany
- 28 Clinic for Cardiology and Pneumology, Georg August University Goettingen, Goettingen, Germany
- 29 Vincentius-Diakonissen Hospital, Karlsruhe, Germany
- 30 Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 31 DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg, Kiel/Luebeck, Hamburg, Germany
- 32 Department of Cardiology, Technische Universität München, Deutsches Herzzentrum München, Munich, Germany
- 33 DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
- 34 Medical Center, University of Ulm, Ulm, Germany
- 35 Service de Cardiologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland
- 36 Department of Cardiology, John Radcliffe Hospital, Oxford University Hospitals, Oxford, UK
- 37 Department of Cardiology, Kantonsspital Lucerne, Lucerne, Switzerland
- 38 Department of Cardiology, Kantonsspital Winterthur, Winterthur, Switzerland
- 39 Heart Center, Turku University Hospital and University of Turku, Turku, Finland
- 40 Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
- 41 Department of Cardiology, King's College Hospital, London, UK
- 42 Department of Cardiology, University Hospital Basel, Basel, Switzerland
- 43 Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
- 44 Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand
- 45 Department of Cardiology and Cardiac Imaging Center, University Hospital of Rangueil, Toulouse, France
- 46 Intensive Coronary Care Unit, Named After N. Pirogov, Moscow City Hospital# 1, Moscow, Russia
- 47 First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM) University of Heidelberg, Mannheim, Germany
- 48 DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany
- 49 Third Faculty of Medicine, Charles University in Prague and University Hospital Královské Vinohrady, Prague, Czech Republic
- 50 Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
- 51 Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic
- 52 Klinik Für Innere Medizin III, Universitätsklinikum Des Saarlandes, HomburgSaar, Germany
- 53 Marien Hospital Herne, Ruhr University Bochum, Herne, Germany
- 54 Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia
- 55 Center of Cardiology of the, Santa Maria University Hospital, CHULN, University of Lisbon, Lisbon School of Medicine, Lisbon Academic Medical Center, Lisbon, Portugal
- 56 Klinik Und Poliklinik Für Innere Medizin II, Universitätsklinikum Regensburg, Regensburg, Germany
- 57 Local Health Unit N.8, Cardiology Unit, Arzignano, Vicenza, Italy
- 58 Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
- 59 Department of Cardiology, Chiba Emergency Medical Center, Chiba, Japan
- 60 Division of Cardiology, Kimitsu Central Hospital, Kisarazu, Japan
- 61 Dorset Heart Centre, Royal Bournemouth Hospital, Bournemouth, UK
- 62 Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
- 63 Division of Cardiology, Heart and Vascular Center, University of Iowa, Iowa City, IA, USA
- 64 Department of Internal Medicine I, University Hospital Jena, Friedrich-Schiller-University Jena, Jena, Germany
- 65 Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Turin, Italy
- 66 Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland
- 67 Department of Cardiology, E.P.E, Centro Hospitalar Universitário de São João, Porto, Portugal
- 68 Department of Cardiology, Basil Hetzel Institute, Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia
- 69 Department of Internal Medicine, Cardiology and Angiology, Magdeburg University, Magdeburg, Germany
- 70 Berlin Institute of Health (BIH), Berlin, Germany
- 71 Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
- 72 Department of Internal Medicine/Cardiology, Heart Center Leipzig at Leipzig University, and Leipzig Heart Science, Leipzig, Germany
- 73 Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy
- 74 Department of Cardiology, National University Heart Centre, Singapore, Singapore

- ⁷⁵ Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan
- ⁷⁶ Department of Internal Medicine and Cardiology, Herzzentrum Dresden, Technische Universität Dresden, Dresden, Germany
- ⁷⁷ Städtisches Klinikum Dresden, Klinik Für Kardiologie, Dresden, Germany
- ⁷⁸ Center for Molecular Cardiology, Schlieren Campus, University of Zurich, Zurich, Switzerland

- ⁷⁹ Royal Brompton and Harefield Hospitals Trust, Imperial College and King's College, London, UK
- ⁸⁰ Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands
- ⁸¹ Division of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
- ⁸² SwissCardioVascular Clinic (SwissCVC), Private Hospital Bethanien, Zurich, Switzerland